AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31888745 — intervention group
Group type: EXPERIMENTAL
Intervention: CT MEWS/SBAR guide
Number of subjects: 292
Study 31888745 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 292
Study 28478041 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention (n=211)
Number of subjects: 1267
Study 28478041 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week weight-management programme (n=528)
Number of subjects: 1267
Study 28478041 — intervention group
Group type: EXPERIMENTAL
Intervention: 52-week weight-management programme (n=528)
Number of subjects: 1267
Study 24975199 — intervention group
Group type: EXPERIMENTAL
Intervention: AFL-dPDT
Number of subjects: 16
Study 24975199 — intervention group
Group type: COMPARATOR
Intervention: dPDT
Number of subjects: 16
Study 24975199 — intervention group
Group type: COMPARATOR
Intervention: cPDT
Number of subjects: 16
Study 24975199 — intervention group
Group type: COMPARATOR
Intervention: AFL
Number of subjects: 16
Study 23958271 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone
Number of subjects: 1200
Study 23958271 — intervention group
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Number of subjects: 1200
Study 23958271 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1200
Study 21163311 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively framed attitude intervention
Number of subjects: 349
Study 21163311 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively framed attitude intervention
Number of subjects: 349
Study 21163311 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Behavioural Control (PBC) intervention
Number of subjects: 349
Study 21163311 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 349
Study 18482867 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian (300 mg nightly for 2 weeks)
Number of subjects: 16
Study 18482867 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nightly for 2 weeks)
Number of subjects: 16
Study 17118503 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber hand placed at varying distances (17.5‐67.5cm)
Number of subjects: 0
Study 17118503 — intervention group
Group type: EXPERIMENTAL
Intervention: Time taken to elicit the illusion
Number of subjects: 0
Study 15090577 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term video EEG (SVEEG) recordings
Number of subjects: 143
Study 11332873 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicilina 250 mg/5 ml oral suspension
Number of subjects: 48
Study 11332873 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicilina 500 mg capsule
Number of subjects: 48
Study 11332873 — intervention group
Group type: COMPARATOR
Intervention: Amoxil 250 mg/5 ml oral suspension
Number of subjects: 48
Study 11332873 — intervention group
Group type: COMPARATOR
Intervention: Amoxil capsule 500 mg
Number of subjects: 48
Study 9440359 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction segment centered at the tip of the test segment
Number of subjects: 0
Study 9440359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral displacement of induction segment from the tip of the test segment
Number of subjects: 0
Study 9440359 — intervention group
Group type: EXPERIMENTAL
Intervention: Pair of induction segments on each side of the tip of the test segment
Number of subjects: 0
Study 9440359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed position and orientation of an induction segment
Number of subjects: 0
Study 7816289 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF (0.83 microgram/min)
Number of subjects: 7
Study 7816289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3404378 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous oxytocin infusion
Number of subjects: 20
Study 3404378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous oxytocin infusion (every 8 minutes)
Number of subjects: 20
Study 3404378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous oxytocin infusion
Number of subjects: 20
Study 28102098 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice PLUS+ (JP) for 12 weeks, n = 72
Number of subjects: 134
Study 28102098 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks, n = 62
Number of subjects: 134
Study 28102098 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice PLUS+ (JP) use following the initial 12-week trial
Number of subjects: 134
Study 28108777 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Matrix‐Induced Chondrogenesis (AMIC®)
Number of subjects: 47
Study 28108777 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (MFx)
Number of subjects: 47
Study 26637812 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC units stored 25 to 35 days (longer-storage group; n=145)
Number of subjects: 290
Study 26637812 — intervention group
Group type: COMPARATOR
Intervention: RBC units stored 1 to 10 days (shorter-storage group; n=145)
Number of subjects: 290
Study 26637812 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 290
Study 23545926 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid with lidocaine (HA+L)
Number of subjects: 119
Study 23545926 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 119
Study 23545926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HA and HA+L
Number of subjects: 119
Study 20887146 — intervention group
Group type: EXPERIMENTAL
Intervention: OP‐1 Putty
Number of subjects: 336
Study 20887146 — intervention group
Group type: COMPARATOR
Intervention: Autogenous iliac crest bone graft
Number of subjects: 336
Study 20887146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 336
Study 18373141 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support (CDS) for 18 months
Number of subjects: 2027
Study 18373141 — intervention group
Group type: COMPARATOR
Intervention: Usual care without computerized support
Number of subjects: 2027
Study 16637317 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic flexible hysteroscopy
Number of subjects: 569
Study 16637317 — intervention group
Group type: COMPARATOR
Intervention: Classical endometrial curettage
Number of subjects: 569
Study 12731685 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months of case management delivered by paraprofessionals
Number of subjects: 0
Study 12731685 — intervention group
Group type: COMPARATOR
Intervention: Brief contact condition
Number of subjects: 0
Study 12731685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 0
Study 12731685 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of case management received
Number of subjects: 0
Study 10980887 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent dual-chamber pacing
Number of subjects: 140
Study 10980887 — intervention group
Group type: COMPARATOR
Intervention: Placebo effect from pacemaker implantation
Number of subjects: 140
Study 8764799 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/ml latanoprost once daily
Number of subjects: 30
Study 8764799 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms/ml latanoprost twice daily
Number of subjects: 30
Study 8764799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1530677 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PCB)
Number of subjects: 0
Study 1530677 — intervention group
Group type: EXPERIMENTAL
Intervention: Amezinium (AMZ)
Number of subjects: 0
Study 1530677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE)
Number of subjects: 0
Study 1530677 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (MDD)
Number of subjects: 0
Study 1530677 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxilofrine (OXF)
Number of subjects: 0
Study 3968001 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h thermal dehydration followed by 2 h head‐out water immersion
Number of subjects: 9
Study 3968001 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h thermal dehydration followed by 2 h chair rest
Number of subjects: 9
Study 3968001 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h thermal dehydration
Number of subjects: 9
Study 3968001 — intervention group
Group type: COMPARATOR
Intervention: 6 h of rest in the supine position
Number of subjects: 9
Study 30796036 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab treatment
Number of subjects: 180
Study 30796036 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab treatment (after exclusion of lowest HER2 expressers)
Number of subjects: 180
Study 29990661 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-CAT (n=52)
Number of subjects: 95
Study 29990661 — intervention group
Group type: COMPARATOR
Intervention: CAT minus narrative reformulation (CAT-NR, n=43)
Number of subjects: 95
Study 26435365 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart
Number of subjects: 394
Study 26435365 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30
Number of subjects: 394
Study 25007693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine 100 microgram/kg before skin incision
Number of subjects: 70
Study 25007693 — intervention group
Group type: COMPARATOR
Intervention: Ilioinguinal/iliohypogastric nerve block with 0.25 ml/kg bupivacaine 0.5% before skin incision
Number of subjects: 70
Study 25007693 — intervention group
Group type: COMPARATOR
Intervention: Ilioinguinal/iliohypogastric nerve block
Number of subjects: 70
Study 25007693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 70
Study 23158942 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine for promoting blood circulation and removing blood stasis
Number of subjects: 48
Study 23158942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19283561 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low dose naltrexone (VLNTX) 0.125 or 0.250 mg per day
Number of subjects: 96
Study 19283561 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low dose naltrexone (VLNTX)
Number of subjects: 96
Study 19283561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 17224720 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (4 mg/d initiated, titrated to a maximum of 16 mg/d)
Number of subjects: 232
Study 17224720 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 232
Study 17224720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 15031340 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (UK) + Benazepril (BZ)
Number of subjects: 71
Study 15031340 — intervention group
Group type: COMPARATOR
Intervention: Benazepril (BZ) alone
Number of subjects: 71
Study 11772224 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial splenic autotransplantation
Number of subjects: 20
Study 11772224 — intervention group
Group type: COMPARATOR
Intervention: Control group (splenectomy)
Number of subjects: 20
Study 9839657 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer Factor (TF)
Number of subjects: 28
Study 9839657 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 28
Study 8205601 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergized natural pyrethrins mousse (single application, 10-minute duration)
Number of subjects: 52
Study 8205601 — intervention group
Group type: COMPARATOR
Intervention: Permethrin creme rinse (control)
Number of subjects: 52
Study 8205601 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergized natural pyrethrins mousse
Number of subjects: 52
Study 2723116 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 029 (5 to 200 mg)
Number of subjects: 70
Study 2723116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 29405944 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity treadmill exercise for 15 minutes
Number of subjects: 44
Study 29405944 — intervention group
Group type: COMPARATOR
Intervention: Control group (sat for 15 minutes)
Number of subjects: 44
Study 27322814 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (ET receptor antagonist)
Number of subjects: 36
Study 27322814 — intervention group
Group type: COMPARATOR
Intervention: ET-1 stimulation
Number of subjects: 36
Study 25233646 — intervention group
Group type: EXPERIMENTAL
Intervention: Floating-needle therapy combined with rehabilitation training
Number of subjects: 100
Study 25233646 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture combined with rehabilitation training
Number of subjects: 100
Study 24211338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 24211338 — intervention group
Group type: COMPARATOR
Intervention: Light therapy (LT)
Number of subjects: 0
Study 24211338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) + Light therapy (CBT + LT)
Number of subjects: 0
Study 20444568 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained clinicians
Number of subjects: 403
Study 20444568 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 403
Study 18349800 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y‐DOTA‐D‐Phe(1)‐Tyr(3)‐octreotide
Number of subjects: 6
Study 18349800 — intervention group
Group type: COMPARATOR
Intervention: (111)In‐DTPA‐D‐Phe(1)‐octreotide
Number of subjects: 6
Study 17033231 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT+TAM therapy
Number of subjects: 164
Study 17033231 — intervention group
Group type: COMPARATOR
Intervention: CAF therapy
Number of subjects: 164
Study 12689404 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral needle ablation (TUNA)
Number of subjects: 59
Study 12689404 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 59
Study 10735896 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Number of subjects: 288
Study 10735896 — intervention group
Group type: COMPARATOR
Intervention: Procarbazine (PCB)
Number of subjects: 288
Study 9366769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 24
Study 9366769 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 24
Study 9366769 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose in lactated Ringer's solution (D5RL)
Number of subjects: 24
Study 9366769 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in water (D5W)
Number of subjects: 24
Study 1412183 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin, INR = 2.5 - 4.2 (n = 34)
Number of subjects: 64
Study 1412183 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA), 300 mg/d (n = 30)
Number of subjects: 64
Study 3997967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 38
Study 3997967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30897198 — intervention group
Group type: EXPERIMENTAL
Intervention: bIgG against CS17
Number of subjects: 36
Study 30897198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30897198 — intervention group
Group type: EXPERIMENTAL
Intervention: bIgG against CsbD
Number of subjects: 36
Study 30530821 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioural intervention
Number of subjects: 272
Study 30530821 — intervention group
Group type: COMPARATOR
Intervention: Leaflet on healthy living (comparator)
Number of subjects: 272
Study 26659245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scissors dissection (fundus-first approach)
Number of subjects: 169
Study 26659245 — intervention group
Group type: COMPARATOR
Intervention: Diathermy hook dissection (starting from the triangle of Calot)
Number of subjects: 169
Study 25080537 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (ND)
Number of subjects: 166
Study 25080537 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 166
Study 22553047 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertising image used in the health communication campaign 'Mummy Drinks Baby Drinks'
Number of subjects: 690
Study 19357113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamapimod (up to 300 mg once daily)
Number of subjects: 0
Study 19357113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19357113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamapimod
Number of subjects: 0
Study 18519297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=237)
Number of subjects: 457
Study 18519297 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=220)
Number of subjects: 457
Study 17022846 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly absorbed paracetamol tablet (PS)
Number of subjects: 30
Study 17022846 — intervention group
Group type: COMPARATOR
Intervention: Standard paracetamol tablet (P)
Number of subjects: 30
Study 14581655 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg nasal spray
Number of subjects: 816
Study 14581655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 816
Study 10887232 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood clot (ABCS)
Number of subjects: 100
Study 10887232 — intervention group
Group type: COMPARATOR
Intervention: No autologous blood clot
Number of subjects: 100
Study 7490815 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.4 mg yohimbine plus 10 mg isoxsuprine 3 times daily
Number of subjects: 20
Study 7490815 — intervention group
Group type: COMPARATOR
Intervention: 400 mg pentoxifylline 3 times daily
Number of subjects: 20
Study 1416272 — intervention group
Group type: EXPERIMENTAL
Intervention: Group EF: 5 micrograms.kg‐1 of fentanyl followed by 0.3 mg.kg‐1 of etomidate.
Number of subjects: 24
Study 1416272 — intervention group
Group type: COMPARATOR
Intervention: Group F: 30 micrograms.kg‐1 of fentanyl.
Number of subjects: 24
Study 4000854 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb movements (experimental groups)
Number of subjects: 88
Study 4000854 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb movements (experimental groups)
Number of subjects: 88
Study 4000854 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct practice on the criterion task (Exp. 2)
Number of subjects: 88
Study 4000854 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant practice on a modification of the criterion task (Exp. 2)
Number of subjects: 88
Study 4000854 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice on several different modifications of the criterion task (Exp. 2)
Number of subjects: 88
Study 4000854 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of practice (general conclusion)
Number of subjects: 88
Study 31704108 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Empire campaign treatment
Number of subjects: 30
Study 31704108 — intervention group
Group type: COMPARATOR
Intervention: Control markets
Number of subjects: 30
Study 30681410 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 480
Study 30681410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 28759333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern: ABCDE with photorealistic images
Number of subjects: 92
Study 28759333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern: UDS with photorealistic images
Number of subjects: 92
Study 28759333 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrations
Number of subjects: 92
Study 28759333 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorealistic images with high self-efficacy
Number of subjects: 92
Study 28759333 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorealistic images with mean or lower self-efficacy
Number of subjects: 92
Study 25962788 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated motivational interviewing and cognitive behavioural therapy
Number of subjects: 0
Study 25962788 — intervention group
Group type: COMPARATOR
Intervention: Therapist-rated alliance
Number of subjects: 0
Study 25962788 — intervention group
Group type: COMPARATOR
Intervention: Client-rated alliance
Number of subjects: 0
Study 25962788 — intervention group
Group type: COMPARATOR
Intervention: Client insecure attachment avoidance
Number of subjects: 0
Study 23463680 — intervention group
Group type: EXPERIMENTAL
Intervention: Low muscle temperature (TmL)
Number of subjects: 15
Study 23463680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 15
Study 21569510 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session standardised curriculum based on the comprehensive social influence model
Number of subjects: 7079
Study 21569510 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 7079
Study 18070931 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 40 microg
Number of subjects: 661
Study 18070931 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg
Number of subjects: 661
Study 18070931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study 17066118 — intervention group
Group type: COMPARATOR
Intervention: Medial branch blocks using bupivacaine (Control Group I)
Number of subjects: 60
Study 17066118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical medial branch blocks with bupivacaine and Sarapin (Group II)
Number of subjects: 60
Study 17066118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical medial branch blocks with bupivacaine and betamethasone (Group III)
Number of subjects: 60
Study 17066118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical medial branch blocks with bupivacaine, Sarapin, and betamethasone (Group IV)
Number of subjects: 60
Study 17066118 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroid group (combined Group I and II)
Number of subjects: 60
Study 17066118 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group (combined Group III and IV)
Number of subjects: 60
Study 14984643 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based self-efficacy coaching
Number of subjects: 0
Study 14984643 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 0
Study 14984643 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention
Number of subjects: 0